Name: Frontier Score for "An Oral GLP-1 Pill Delivers Injectable-Level Weight Loss"
Rating: 43
Author: Frontier

What it is

In a phase 3 trial of 3,127 adults with obesity but not diabetes, once-daily oral orforglipron produced a mean weight change of -11.2% at the top 36 mg dose over 72 weeks, compared with -2.1% for placebo. At that dose 54.6% of patients lost at least 10% of body weight and 18.4% lost at least 20%. Being a non-peptide small molecule, it can be made and taken as a simple pill rather than an injection.

Why it matters

Existing GLP-1 drugs are injectable peptides that are costly and supply-constrained. Orforglipron is the first oral small-molecule GLP-1 agonist to succeed in phase 3, reaching efficacy in the range of injectables while cutting mean body weight by -11.2% at the top dose versus -2.1% on placebo. A daily pill that is cheaper to manufacture could widen access to metabolic therapy dramatically.

Underlined numbers link to their source. Every metric and quoted figure is listed under Sources and data below.

Filed underobesity, GLP-1, metabolic, phase-3, drug

Watch

A short explainer of this result.

Scored 2026-11-13How scoring works

The Frontier Score, in full

How this entry's score is built, term by term. Open any pillar to see each sub-metric's raw value, how it maps to 0 to 100, and a link to its source (OpenAlex for most sub-metrics that combine several sources, NIH iCite where its ratio is part of field-normalized impact).

The three pillars as one shape: a result strong on every axis fills the triangle.

How the Frontier Score is calculated for this breakthrough
Term	Score	Weight	Points
EvidenceHow established and verifiable the result is.	83	× 0.25	20.7
ImpactHow much the result matters, judged field-relative and by current momentum.	90	× 0.25	22.4
NoveltyHow genuinely new the result is, and how fast-moving.	45	× 0.50	22.4
Weighted pillars			65.4
Frontier recency14 months since publication		× 0.65
IntegrityNot retracted		× 1
Frontier Score			43

Confidence: SettledEstablished evidence: about 167 citations across 5 independent indices. Corroborated beyond citations (1 clinical trial).

Every sub-metric, traced to its source

EvidenceHow established and verifiable the result is.83

Evidence sub-metrics
Sub-metric	Raw value	0 to 100	Weight	Points	Source
Peer review & venueWhether the work has cleared peer review, and how selective its venue is. Peer review is necessary but not sufficient: before citations accrue, a fresh result in one of the five general flagships (Nature, Science, Cell, NEJM, the Lancet) is a stronger evidence signal than one in a selective specialist or society journal, which in turn outranks one in a legitimate but very high-volume mega-journal, and any of them outranks a preprint that has not been reviewed at all.Maps to 0 to 100: Peer-reviewed article graded by venue tier: flagship journal (Nature, Science, Cell, NEJM, the Lancet) 100; selective journal (every other journal the index admits: the specialist journals of those families, JAMA, PNAS, Physical Review Letters and X) 90; high-volume mega-journal (Nature Communications, Science Advances) 78; venue not recorded 88. Other records: review 90, book 70, dataset 60, preprint 45, an article that has not been peer reviewed 45, other 55.	Peer-reviewed, flagship journal	100	0.30	30.0	OpenAlex type / primary_location / source
CorroborationIndependent corroboration that the result is on the record and reaching beyond a single source, read as the BREADTH of independent records rather than the size of the citation pile. Counts how many of the five independent citation indices (OpenAlex, Crossref, Semantic Scholar, OpenCitations, Europe PMC) report a citation count for the work at all, zero included, plus orthogonal, non-citation lines of corroboration: citation in Wikipedia, registered clinical trials or clinical citations, released datasets or software or a repository copy, public funding on record, and technical-community discussion. Citation MAGNITUDE is deliberately judged under Impact, not here, so Evidence and Impact measure genuinely different things instead of both rewarding the same citation pile twice.Maps to 0 to 100: Starts at 28 and rises by 9 for each of the five independent citation indices that returns a citation count for the work (zero counts; OpenCitations returns zero even for a DOI it does not hold) and by 6 for each orthogonal non-citation line (Wikipedia, clinical trials or clinical citations, open datasets, software or a repository copy, public funding, community discussion), up to the top of the 0-100 scale.	5 of 5 citation indices report a count, 1 independent non-citation line	79	0.30	23.7	OpenAlex, Crossref, Semantic Scholar, OpenCitations, Europe PMC, DataCite, NIH RePORTER, Wikipedia, Hacker News count of indices that report a count for the work + orthogonal reach
VerifiabilityHow openly the result can be read, reused, and reproduced. Rewards open access, a Creative Commons BY or CC0 license, a green repository copy anyone can archive, openly minable full text, and released datasets or software a reader can actually run. Cross-checked across OpenAlex, Unpaywall, Europe PMC, and DataCite.Maps to 0 to 100: Closed access 45; open access 88; any Creative Commons BY license (including the NC, ND and SA variants) or CC0 100. A repository copy raises the floor to 85, openly minable full text to 90, and released data or software to 92.	Closed access	45	0.20	9.0	OpenAlex, Unpaywall, Europe PMC, DataCite is_oa / license / has_repository_copy / open datasets
IntegrityRetraction and post-publication correction status. A retracted result is not evidence of anything and collapses the whole Frontier Score; a correction or expression of concern is a softer flag. A correction the publisher labels as its own error (a Publisher Correction) is not a flag on the work. Read across OpenAlex and Crossref (both update-to and updated-by notices).Maps to 0 to 100: Clean 100 (also when the only notice is a Publisher Correction); a correction or expression of concern 75; retracted 0. Flagged if OpenAlex OR Crossref records the notice.	No retraction or concern on record	100	0.20	20.0	OpenAlex, Crossref is_retracted / update-to / updated-by

ImpactHow much the result matters, judged field-relative and by current momentum.90

Impact sub-metrics
Sub-metric	Raw value	0 to 100	Weight	Points	Source
Field-normalized impactImpact relative to the world average for the same field, year, and type, so a small field and a large field are judged fairly. Triangulates three independent field-normalized measures: OpenAlex's Field-Weighted Citation Impact, its citation percentile within the exact field-and-year cohort, and the NIH iCite Relative Citation Ratio. 1.0x is average; the percentile is the share of same-field, same-year work it out-cites.Maps to 0 to 100: Each ratio (1.0 = field average) maps 1.0 to 50, 3.0 to 75, 9.0 to 90; the field+year percentile maps directly (top 1% -> ~99). The available measures are averaged. When none is available yet (very recent work), this sub-metric is left out and Impact is computed from the others.	86.1x FWCI, 35.5x RCR, top 0.0% of field-year vs field	99	0.45	44.4	OpenAlex, NIH iCite fwci / citation_normalized_percentile / relative_citation_ratio
Influential citationsCitations that genuinely build on the work rather than mention it in passing (Semantic Scholar's influential-citation measure). A sharper signal of real impact than a raw count.Maps to 0 to 100: Saturating: 15 influential citations maps to 50, and none maps to 0. When Semantic Scholar has no measure for the work, this sub-metric is left out and Impact is computed from the others.	28 influential	65	0.20	13.0	Semantic Scholar influentialCitationCount
Citation velocityCitations received in the trailing twelve months (estimated from yearly citation counts: this year's so far plus the share of last year's that falls inside the window), judged as a rate rather than a lifetime total. Momentum is what a frontier index cares about: a result being taken up fast right now is landing, whether its lifetime pile is large or still small. Where an expected field citation rate is known, the momentum is also read relative to it, so a fast-moving result in a quiet field is not overlooked.Maps to 0 to 100: Saturating: 30 citations in the last twelve months maps to 50. When NIH iCite provides the field's expected rate, this is blended evenly with the ratio of observed to expected momentum.	208 in last 12 months (24.3x field rate)	92	0.35	32.1	OpenAlex, NIH iCite counts_by_year / field_citation_rate

NoveltyHow genuinely new the result is, and how fast-moving.45

Novelty sub-metrics
Sub-metric	Raw value	0 to 100	Weight	Points	Source
Conceptual noveltyHow genuinely new the contribution is, measured at publication from the work's OWN content, not its date: how atypical its combination of research areas is versus all prior work, and whether it builds on a broad, deep base rather than only the newest papers in a fast-moving area. This is what separates a real advance from a recent-but-commodity result, and it needs no forward citations, so it is stable for brand-new work. An honestly noisy proxy (even state-of-the-art novelty measures agree only moderately with expert judgment), so it carries bounded weight and never drives the ranking alone.Maps to 0 to 100: Two publication-time signals, each 0-100. The primary one is atypical combination: how unusual the work's median pairing of research topics is versus the prior literature, by pointwise mutual information (a pairing made far more often than chance scores low). The second, foundational reach (the median age of the work's references and the share older than five years), can only lift it: when reach is higher, the score rises by 35% of the gap, and it is never lowered. When only one signal is measurable it is used alone; when neither is (a work too thin in topics or references), this sub-metric is left out and Novelty is computed from the other three. A review is damped to 60%.	Median topic pairing Diabetes Treatment and Management x Bariatric Surgery and Outcomes (7,463 prior works made this pairing); builds on refs a median 2.2y deep	26	0.45	11.6	OpenAlex topics + referenced_works (publication-time)
RecencyHow recently the work appeared. The frontier is now, so newer scores higher.Maps to 0 to 100: Exponential decay with a 12-month half-life from the publication date.	14 months old	45	0.30	13.4	OpenAlex publication_date
Attention accelerationWhether attention is rising: citations in the latest full year versus the year before. Accelerating interest signals an active, opening frontier.Maps to 0 to 100: Latest/prior-year ratio: 1x maps to 50, 2x to 75, 4x to 100. The prior year counts as at least 3 citations, so a jump from one citation to a few is not read as explosive growth. With no citations in the latest full year it reads as unknown, and unknown is neutral (50).	4.0x rising	100	0.10	10.0	OpenAlex counts_by_year
Edge of reviewPreprints sit ahead of the peer-review process and brand-new papers have only just cleared it. Both earn novelty here (while a preprint is discounted under Evidence), because that is where the frontier forms first.Maps to 0 to 100: Preprint 95; any other record 80 when under 6 months old, 65 under 18 months, 45 after that.	Peer-reviewed record	65	0.15	9.8	OpenAlex type / publication_date

ProvenanceAll sources

Sources and data

The source figures behind this entry, grouped by the source that holds them: up to five citation indices cross-checked, field-normalized impact, then real-world reach (Wikipedia, community discussion, clinical trials, released data and public funding) where it exists. Each value links to its record.

OpenAlex

Primary record

Total citations: 218
Field-weighted citation impact: 86.1x field average
Citation percentile: Top 0.1% of its field-year
Citations, recent 12 months: 208
Publication date: 2025-09-16
Access: Closed access

Crossref

Citations: 209
Works it builds on: 27
Funders on record: 1

Semantic Scholar

Citations, all versions: 167
Influential citations: 28

OpenCitations

Citations: 30

Europe PMC

Citations: 65

NIH iCite

Relative Citation Ratio: 35.53 (NIH-funded median 1.0)
Potential to translate: 95%
Cited by clinical articles: 14

ClinicalTrials.gov

Registered clinical trials: 1 (to phase 3)

OpenAlex record Read it in New England Journal of Medicine

Figures quoted in the write-up

Figure	Value	Source
Weight change, 36 mg dose (Mean change from baseline to week 72)	-11.2%	New England Journal of Medicine
Weight change, placebo (Mean change over same period)	-2.1%	New England Journal of Medicine
Lost 10%+ body weight (36 mg) (vs 12.9% on placebo)	54.6%	New England Journal of Medicine
Lost 20%+ body weight (36 mg) (vs 2.8% on placebo)	18.4%	New England Journal of Medicine
Patients randomized (Multinational, double-blind)	3,127	New England Journal of Medicine
Trial duration (Adjunct to diet and activity)	72 weeks	New England Journal of Medicine
Top once-daily dose (Once-daily doses of 6 mg, 12 mg or 36 mg were compared with placebo)	36 mg	New England Journal of Medicine
Weight-loss threshold (54.6% of the 36-mg group had a reduction of 10% or more (placebo 12.9%))	10%	New England Journal of Medicine
Higher weight-loss threshold (18.4% of the 36-mg group had a reduction of 20% or more (placebo 2.8%))	20%	New England Journal of Medicine

For the authors

Show this score where your work lives

A badge for your lab page, your CV or the paper's code repository. It links readers to this entry, and it always carries the entry's current score.

Live preview

<a href="https://frontierresearch.co/breakthroughs/an-oral-glp-1-pill-delivers-injectable-level-weight-loss?utm_source=badge&amp;utm_medium=badge&amp;utm_campaign=author-kit"><img src="https://frontierresearch.co/api/badge/W4414222945.svg" alt="Frontier Score for this paper" height="20"></a>

For a lab or personal website, a CV page, or anywhere that takes HTML.

The number is live. The badge is drawn from the same signals as this page, so it never shows a score the entry does not. Every entry is re-checked weekly against the same public sources, and a result's standing eases as it ages, so the active edge of the field stays on top. How scoring works

Your other papers. The free paper check shows any paper's field-weighted citation impact, its citations in five open indexes and any retraction on record, whether or not it is in the index, and the researcher check does it for your whole record from your ORCID iD.

Something wrong or out of date? Write to hello@frontierresearch.co and the entry will be corrected.

Biomedicine & HealthThe whole field

Biomedicine & Health · Notable

Tracing the spread of Germanic languages using ancient genomics

Ancient DNA suggests Germanic may have reached Scandinavia some 800 years later than assumed

E 96I 59N 82Oct 28, 2026

Biomedicine & Health · Notable

Clostridium perfringens Delta toxin targets CD9 to drive NEC and brain injury

E 92I 37N 91Oct 28, 2026

Biomedicine & Health · Notable

Efficient and accurate mixed model association tool for single-cell eQTL analysis

In 1.2 million immune cells, a single-cell model found 48.8% more eGenes than a standard pooled pipeline

E 90I 53N 78Nov 6, 2026

Back to the Frontier Index, or browse every breakthrough by date.

What it is

Why it matters

Watch

The Frontier Score, in full

Sources and data

OpenAlex

Crossref

Semantic Scholar

OpenCitations

Europe PMC

NIH iCite

ClinicalTrials.gov

Show this score where your work lives

Related on the frontier

Tracing the spread of Germanic languages using ancient genomics

Clostridium perfringens Delta toxin targets CD9 to drive NEC and brain injury

Efficient and accurate mixed model association tool for single-cell eQTL analysis

The week's Biomedicine & Health, scored.